Hemenway Trust Co LLC Purchases 205 Shares of Danaher Co. (NYSE:DHR)

Hemenway Trust Co LLC raised its stake in Danaher Co. (NYSE:DHR) by 0.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 154,941 shares of the conglomerate’s stock after acquiring an additional 205 shares during the period. Danaher makes up 3.3% of Hemenway Trust Co LLC’s holdings, making the stock its 10th biggest holding. Hemenway Trust Co LLC’s holdings in Danaher were worth $38,712,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of DHR. Norges Bank bought a new stake in shares of Danaher in the 4th quarter worth approximately $1,752,382,000. Vanguard Group Inc. lifted its stake in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares during the period. Swedbank AB bought a new stake in Danaher in the 1st quarter valued at about $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after purchasing an additional 2,096,038 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DHR shares. Evercore ISI reduced their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Leerink Partners raised their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research report on Friday. Finally, Stifel Nicolaus boosted their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Trading Up 1.3 %

Shares of DHR stock traded up $3.35 during trading hours on Friday, reaching $268.06. 438,386 shares of the stock traded hands, compared to its average volume of 2,774,216. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $198.55 billion, a PE ratio of 45.52, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The business has a fifty day moving average price of $260.98 and a 200 day moving average price of $255.61.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 earnings per share. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.